Latest News & Features
Americas
Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint. 3 February 2022
article
Tune in to hear from a panel of leading patent attorneys from Europe and the US as they discuss some key strategies for protecting your IP and how to minimize your risk when filing patents internationally. What are the vital considerations for patent prosecutions at both the USPTO and EPO? Hear from our panel how to overcome the latest challenges to patent procurement in both jurisdictions. 3 February 2022
Big Pharma
UK politicians are proposing that the country waive UK registered IP related to vaccines and treatments in the event of a pandemic. 1 February 2022
Americas
Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst. 1 February 2022
article
A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization failing to reach consensus. 1 February 2022
Biotechnology
The US International Trade Commission will investigate whether drug manufacturers used trade secrets to develop a biosimilar of AbbVie’s Humira. 27 January 2022
Americas
AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler. 27 January 2022
article
The World Trade Organization’s TRIPS waiver was proposed back in October 2020 but stalled due to largely developing nations signing up to sponsor the waiver, as many developed nations opposed. 27 January 2022
Generics
A Virginia district court judge has recommended that buyers of cholesterol drug Zetia should not be granted class certification in pay-for-delay litigation against MSD and Glenmark Generics. 27 January 2022
Big Pharma
Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel. 25 January 2022